Empagliflozin in Adults with Chronic Kidney Disease (CKD): Current Evidence and Place in Therapy
Gates B Colbert,1 Hector M Madariaga,2 Anna Gaddy,3 Mohamed E Elrggal,4 Edgar V Lerma5 1Texas A&M University College of Medicine at Dallas, Dallas, TX, USA; 2Department of Internal Medicine, Lahey Hospital & Medical Center, Burlington, MA, USA; 3Department of Internal Medicine, Medical Colle...
Main Authors: | Colbert GB, Madariaga HM, Gaddy A, Elrggal ME, Lerma EV |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2023-02-01
|
Series: | Therapeutics and Clinical Risk Management |
Subjects: | |
Online Access: | https://www.dovepress.com/empagliflozin-in-adults-with-chronic-kidney-disease-ckd-current-eviden-peer-reviewed-fulltext-article-TCRM |
Similar Items
-
Empagliflozin: a new strategy for nephroprotection in diabetes
by: Anton Ivanovich Korbut, et al.
Published: (2017-05-01) -
Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study
by: Phyo T. Htoo, et al.
Published: (2024-02-01) -
Predictive Value of Serum Hepcidin Levels for the Risk of Incident End-Stage Kidney Disease in Patients with Chronic Kidney Disease: The KNOW-CKD
by: Sang Heon Suh, et al.
Published: (2024-10-01) -
Empagliflozin—A New Chance for Patients with Chronic Heart Failure
by: Klaudia Kowalska, et al.
Published: (2021-12-01) -
Sodium glucose co-transporter 2 inhibitors (SGLT2i) for pediatric kidney disease: the future is near
by: Gilda M. Portalatin, et al.
Published: (2025-01-01)